Dyne Therapeutics is set to present preclinical data on four investigational therapies for Duchenne muscular dystrophy (DMD) at the 27th Annual Neuromuscular Study Group Scientific Meeting in San Antonio, Texas, from September 25 to 27.
The company will showcase exon-skipping results for DYNE-253, DYNE-245, DYNE-244, and DYNE-255 during a poster session on September 25 from 5:00 to 7:00 p.m. CT. Each candidate targets a distinct DMD mutation amenable to exon skipping, with DYNE-253, DYNE-245, and DYNE-244 designed for exons 53, 45, and 44, respectively. DYNE-255 focuses on exon 55.
Preclinical findings for DYNE-253 will include pharmacokinetic and pharmacodynamic data, alongside exon skipping and dystrophin levels evaluated in a Del52 mouse model of DMD. The remaining three candidates will present in vitro exon-skipping results.
All four therapies utilize Dyne’s FORCE platform, a technology also employed in DYNE-251, an exon 51-targeting DMD candidate currently under U.S. FDA review. The company is advancing all four programs into investigational new drug (IND)-enabling studies.
Dyne’s clinical pipeline centers on genetically driven neuromuscular diseases, with active programs in Duchenne muscular dystrophy and myotonic dystrophy type 1. Preclinical efforts are underway for facioscapulohumeral muscular dystrophy, Pompe disease, and additional DMD mutations.
